By Dale Curtis Jr., President, Astrix Technology Group
As the complexity of the global R&D environment has grown over the last several decades, biopharma companies have found it increasingly difficult to accomplish scalable growth with their in-house team alone. This has led to the practice of outsourcing becoming commonplace as a way to reduce costs.
In the accounting and consultancy firm Deloitte’s comprehensive 2014 Global Outsourcing and Insourcing Survey, 53% of respondents indicated that they were currently outsourcing part of their IT function, while 26% indicated that they planned to in the future. Over 30% of organizations participating in the Deloitte 2016 Global Outsourcing Survey indicated that they planned to do more outsourcing in the future.